Rizvi Imran, Obaid Girgis, Bano Shazia, Hasan Tayyaba, Kessel David
Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, 02114.
Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan, 48201.
Lasers Surg Med. 2018 Jul;50(5):499-505. doi: 10.1002/lsm.22813. Epub 2018 Mar 11.
A relatively low level of lysosomal photodamage has been shown capable of promoting the efficacy of photodamage simultaneously or subsequently directed to mitochondrial/ER sites. The procedure has hitherto involved the use of two photosensitizing agents that require irradiation at two different wavelengths and different formulation techniques. This, together with different pharmacokinetic profiles of the photosensitizers, adds a layer of complexity to a protocol that we have sought to circumvent. In this study, liposomal formulations were used to direct photodamage created by benzoporphyrin derivative (BPD, Verteporfin) to lysosomes, mitochondria and the ER. This resulted in the development of an optimal targeting profile using a single agent and a single wavelength of activating irradiation.
MATERIALS/METHODS: These studies were carried out in monolayer cultures of OVCAR5 tumor cells. BPD localization was modified by lipid anchoring and formulation in liposomes, and was assessed by fluorescence microscopy. Irradiation was carried out at 690 ± 10 nm with photodamage assessed also using fluorescent probes and microscopy.
BPD normally localizes in a wide variety of sub-cellular loci that include both mitochondria and the ER, but lysosomes are spared from photodamage. Using a liposomal formulation containing BPD anchored to a lipid resulted in the targeting of lysosomes. A mixture of liposomes containing "free" and "anchored" BPD was shown to significantly promote photokilling. Eliminating cholesterol from the formulation of the anchored product enhanced lysosomal photodamage; prior studies had revealed that excess cholesterol can have a cytoprotective effect when lysosomes are the PDT target.
The ability of a liposomal formulation to change localization patterns permits directing photodynamic therapy toward specific sub-cellular loci, thereby promoting photokilling. Incorporating chemotherapeutic agents into such formulations could represent a logical next step in assessing the ability of directed photodamage to enhance tumor eradication. Lasers Surg. Med. 50:499-505, 2018. © 2018 Wiley Periodicals, Inc.
已表明相对较低水平的溶酶体光损伤能够同时或随后增强针对线粒体/内质网部位的光损伤效果。该过程迄今涉及使用两种光敏剂,它们需要在两个不同波长下进行照射,且采用不同的制剂技术。这与光敏剂不同的药代动力学特征一起,给我们试图规避的方案增加了一层复杂性。在本研究中,脂质体制剂被用于将由苯并卟啉衍生物(BPD,维替泊芬)产生的光损伤导向溶酶体、线粒体和内质网。这导致使用单一药物和单一激活照射波长开发出了最佳靶向模式。
材料/方法:这些研究在OVCAR5肿瘤细胞的单层培养物中进行。通过脂质锚定和脂质体制剂改变BPD的定位,并通过荧光显微镜进行评估。在690±10nm波长下进行照射,同时也使用荧光探针和显微镜评估光损伤。
BPD通常定位于包括线粒体和内质网在内的多种亚细胞位点,但溶酶体免受光损伤。使用含有锚定在脂质上的BPD的脂质体制剂导致溶酶体靶向。含有“游离”和“锚定”BPD 的脂质体混合物显示出显著促进光杀伤作用。从锚定产物的制剂中去除胆固醇增强了溶酶体光损伤;先前的研究表明,当溶酶体是光动力疗法的靶点时,过量的胆固醇可具有细胞保护作用。
脂质体制剂改变定位模式的能力允许将光动力疗法导向特定的亚细胞位点,从而促进光杀伤。将化疗药物纳入此类制剂可能是评估定向光损伤增强肿瘤根除能力的合理下一步。《激光外科与医学》50:499 - 505,2018年。©2018威利期刊公司